CTLA4 and neoplasm: The data presented herein show that TNF-armed MYXV, as systemically delivered via mixed carrier cells, such as PBMCs, in combination with ICIs such as anti-CTLA-4, anti-PD-1, or anti-PD-L1 can lead to long-term disease-free survival in animals when treatment is initiated early after tumor implantation in the lung.